Efficacy of Extracorporeal Shockwave Therapy of the Perineum for Chronic Pelvic Pain Syndrome in Male Patients: A Pilot Study
Keywords:
Chronic pelvic pain, chronic prostatitis, shockwave therapyAbstract
Chronic pelvic pain syndrome (CPPS) is a complex, multifactorial condition that significantly impairs the quality of life. It is a challenging condition for urologists, as there are no established treatment options and it requires a multimodal approach. This single-arm, prospective study was conducted in a tertiary-level hospital. Men >18 years of age with pelvic discomfort for at least 3 months, without urological abnormalities, a National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score >15, and failure of various pharmacological therapies were enrolled. All patients underwent eight sessions of perineal Low-Intensity Shockwave Therapy (LiSWT) over four weeks, with each session delivering 2400 impulses (frequency of 12 Hz). Treatment response was assessed using the NIH-CPSI score immediately after therapy and at 4, 8, and 12 weeks of follow-up. Twenty-one patients (mean age 42.8 ± 7.9 years) with a mean symptom duration of 12.8 ± 3.2 months, with baseline NIH-CPSI scores of 12 ± 1.58 for pain, 6.8 ± 1.5 for urinary symptoms, 9.35 ± 1.18 for quality of life, and 29.15 ± 2.94 in total. Clinical improvement was observed in 42.8% of patients at four weeks, increasing to 66.7% at eight weeks and 80.9% at twelve weeks. Urinary symptoms showed early improvement, while pain, quality-of-life, and total scores demonstrated improvement by eight and twelve weeks (p < 0.05). The perineal LiSWT is a safe, feasible, and potentially effective treatment option for patients with CPPS.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Nepal Medical College Journal

This work is licensed under a Creative Commons Attribution 4.0 International License.
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.